Addition of simeprevir to peginterferon/ribavirin improves SVR rate among HCV patients
May 1, 2013
Simeprevir improves rates of sustained virologic response and may allow for a 24-week treatment duration when added to interferon-based therapy for chronic hepatitis C, according to data presented at the International Liver Congress in Amsterdam.
In the double blind, phase 3 QUEST-1 study, researchers randomly assigned 394 treatment-naive patients with HCV genotype 1 to either 150 mg oral HCV NS3/4A protease inhibitor simeprevir or placebo, for 12 weeks, plus 48 weeks of pegylated interferon alfa-2a with ribavirin (PR). Patients with HCV RNA below 25 IU/mL after 4 weeks of treatment and undetectable RNA at 12 weeks stopped treatment at 24 weeks. All placebo recipients received 48 weeks of PR therapy.
Full Story »
EASL - Meeting News Coverage @ Healio
Addition of simeprevir to peginterferon/ribavirin improves SVR rate among HCV patients
May 1, 2013
Simeprevir improves rates of sustained virologic response and may allow for a 24-week treatment duration when added to interferon-based therapy for...More »
Alcohol consumption, metabolic risk factors tied to cirrhosis, hepatocellular carcinoma
April 30, 2013
Heavy alcohol consumption and obesity increase the risk for liver-related morbidity and death, while metabolic risk factors also elevate the risk for...More »
Daclatasvir/asunaprevir/NS5B inhibitor effective in treatment-naive HCV patients
April 30, 2013
Treatment-naive patients with chronic hepatitis C experienced high rates of sustained virologic response from a combination of three direct-acting...More »
Probiotics may prevent hepatic encephalopathy among cirrhotic patients
April 29, 2013
Patients with cirrhosis were less likely to develop overt hepatic encephalopathy when taking probiotics than controls in a study presented at the...More »
Faldaprevir/peginterferon/ribavirin improved SVR, shortened therapy for chronic HCV
April 29, 2013
The addition of faldaprevir to pegylated interferon/ribavirin therapy significantly improved rates of sustained virologic response and allowed for shorter...More »
Meeting News Coverage
Everolimus-based immunosuppression post-liver transplant as effective as tacrolimus with better renal function
April 26, 2013
Liver transplant recipients who received everolimus-based immunosuppression with reduced tacrolimus experienced similar results to those treated with...More »
Interferon-free, triple-DAA regimen safe, effective for chronic HCV
April 26, 2013
Nearly all patients with chronic hepatitis C treated with an interferon-free drug regimen for 12 or 24 weeks experienced sustained virologic response in a...More »
Gene variants linked to steatosis, fibrosis, steatohepatitis
April 25, 2013
Variants in the PNPLA3, GCKR, TRIB1 and PPP1R3B genes are associated with histological factors of nonalcoholic fatty liver disease, according to data...More »
No comments:
Post a Comment